BioSpace News Archive

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer announced that it will present updated data from its blood cancer portfolio at the 63rd Annual Meeting of the American Society of Hematology taking place December 11 – 14, 2021.

I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that an abstract summarizing the most recent clinical data from an ongoing clinical trial of its differentiated CD47 antibody lemzoparlimab, will be presented at the 63rd American Society of Hematology Annual Meeting, taking place December 11 – 14, 2021.

Loxo Oncology at Lilly , a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the pirtobrutinib development program at the American Society of Hematology (ASH) Annual Meeting to be held December 11-14, 2021

Vivera Pharmaceuticals announced that Sahar S. Pugh will join the Company as General Counsel and Vice President of Legal Affairs.

Viracta Therapeutics, Inc. today announced the acceptance of two abstracts for oral presentation and one for a poster presentation at the upcoming 2021 American Society of Hematology (ASH) Annual Meeting, which will be held from December 11-14, 2021, both in Atlanta, Georgia and virtually.

CTI BioPharma Corp. (Nasdaq: CTIC) today announced five poster presentations from the Company’s pacritinib program at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually and in Atlanta, Georgia , December 11-14, 2021 .

Gracell Biotechnologies Inc. announced preclinical data for GC502, an allogeneic chimeric antigen receptor T cell therapy for the treatment of B-cell malignancies, will be presented as a virtual poster at the 63rd American Society of Hematology Annual Meeting and Exposition as part of the “Cellular Immunotherapies: Basic and Translational” session on December 11, 2021 from 5:30 p.m.-7:30 p.m..

AbbVie will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of Hematology Annual Meeting in Atlanta, Georgia.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that three abstracts highlighting data and information from three oncology drug candidates in its pipeline will be presented at the upcoming 63rd Annual American Society of Hematology Annual Meeting to be held December 11 – 14, 2021.

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced initial safety and efficacy findings from its Phase 1b/2 study of IMGN632 in combination with Vidaza® and Venclexta® in patients with relapsed/refractory acute myeloid leukemia.